Effecta Pharma is led by Drs. Paul Edwards and Helmuth van Es.
Dr. Paul Edwards has 18 years of industrial experience and has been involved with the delivery of seven clinical candidates reaching up to Phase II. Paul was previously Vice president of Chemistry for Boehringer Ingelheim ― leading a Department of 74 staff focussed on anti-infective research and has extensive experience with the discovery and development of small molecule antivirals, for example for HCV and CMV. He is co-founder of Effecta Pharma.
Dr. Helmuth van Es, has co-founded Galapagos, BioConsilium, Audion Therapeutics, Antabio, Effecta Pharma and Citryll. He has been involved with numerous (pre)-clinical development programs and is non-executive director of Antabio ― an antibacterial company.